Characterization of response to nivolumab plus ipilimumab (N1I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214

This article has no abstract
Epistemonikos ID: 2a160bfc8bc5476fdc8887386eed4ead336ac617
First added on: Feb 11, 2025